PF icon
Feature Partner

Psylo

Quick Overview of Psylo

Company Status
Public
Private
Non-Profit
Parent Company
CSE Ticker
FSE TICKER
OTC Ticker
TSX TICKER
TSX Venture TICKER
NEO TICKER
NASDAQ TICKER
NYSE TICKER

Company Summary

About

Psylo is Australia’s first psychedelic biotech company focused on developing psychedelic medicines to treat mental illness. The company develops psychedelics drugs to make them accessible as improved treatments to currently available selective serotonin reuptake inhibitors (SSRI) medications using psychedelic molecules, thereby enabling patients to recover from severe mental issues.

Team

Josh Ismin, CEO, is a repeat founder and biotech investor, with a BSBA and MBA from Washington University in St. Louis (where neurologist Marcus E. Rachichle coined the term “Default Mode Network”).  
Sam Banister, CSO, is a leading medicinal chemist with a proven track record in molecular discovery within academia (at University of Sydney, and Stanford) as well as with a variety of biotech startups.